William Richard White
CIK 1778739 · Chief Financial Officer · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$131.1K
Companies
3
Total Filings
73
Lifetime Open-Market Net
-$19.12M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IRON | Director | 1,756 | $74.65 | $131.1K | -$2.96M | 14 | 2026-06-23 |
| Ventyx Biosciences, Inc. (VTYX) Delisted | Director | 7,027 | $13.99 | $98.3K | -$1.17M | 8 | 2026-03-04 |
| Akero Therapeutics, Inc. (AKRO) Delisted | Chief Financial Officer | 0 | $54.65 | $0 | -$14.99M | 41 | 2025-12-09 |
Recent Filings · Page 3 of 8
73 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-08-26 | Akero Therapeutics, Inc. (AKRO) Delisted | Notice (144) | −98,334 | -$2.70M | EDGAR |
| 2024-08-05 | IRON | Mixed | — | -$6.7K | EDGAR |
| 2024-08-01 | IRON | Notice (144) | −9,696 | -$418.5K | EDGAR |
| 2024-07-25 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$3.25M | EDGAR |
| 2024-07-24 | Akero Therapeutics, Inc. (AKRO) Delisted | Notice (144) | −98,333 | -$2.73M | EDGAR |
| 2024-07-18 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | −5,008 | -$767.4K | EDGAR |
| 2024-07-16 | Akero Therapeutics, Inc. (AKRO) Delisted | Notice (144) | −98,333 | -$2.70M | EDGAR |
| 2024-07-03 | IRON | Mixed | — | -$7.3K | EDGAR |
| 2024-06-14 | IRON | Grant (A) | — | $0 | EDGAR |
| 2024-06-13 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −2,831 | -$64.1K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.